Consequently, CXCR2 inhibitors have the potential to reprogram the NASH-HCC tumor immune microenvironment, fostering a more favorable response to immune checkpoint inhibitors (138). The gene discussed is CXCR2; the disease is metabolic dysfunction-associated steatohepatitis.